Hsp90 activation and cell cycle regulation.

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Heat shock protein 90 (Hsp90) is a molecular chaperone crucial for cellular processes and cancer progression.
• Hsp90 inhibitors are investigated as anticancer agents, but their selective toxicity in cancer versus normal tissues is not fully understood.
• Hsp90 is highly expressed in both normal and tumor tissues, posing a challenge for targeted cancer therapy.

Purpose of the Study:

• To investigate the differential utilization and conformational state of Hsp90 in normal versus cancer cells.
• To elucidate the mechanism behind the selective antitumor activity and clinical tolerability of Hsp90 inhibitors like 17-allylamino-geldanamycin (17-AAG).
• To discuss the implications for cell cycle regulation and cancer treatment strategies.

Main Methods:

• Analysis of Hsp90 utilization and conformational changes in normal and malignant cells.
• Assessment of 17-allylamino-geldanamycin (17-AAG) binding affinity in relation to Hsp90 activation state.
• Review of existing findings on Hsp90 function in cell cycle regulation and cancer.

Main Results:

• Hsp90 is largely latent in unstressed normal cells but fully utilized in malignant cells.
• Malignant progression induces an activation-dependent conformational shift in Hsp90.
• This conformational change significantly increases the binding affinity of 17-AAG to Hsp90 in cancer cells.

Conclusions:

• The increased binding affinity of Hsp90 inhibitors to activated Hsp90 in cancer cells explains their selective antitumor activity.
• This mechanism underlies the clinical tolerability of Hsp90 inhibitors, as normal cells with latent Hsp90 are less affected.
• Targeting Hsp90's activated state offers a promising strategy for cancer therapy, impacting cell cycle regulation.